BamSEC and AlphaSense Join Forces
Learn More

Kiora Pharmaceuticals Inc.

NASDAQ: KPRX    
Share price (1/3/25): $3.63    
Market cap (1/3/25): $10.9 million

Material Contracts Filter

EX-10.2
from 8-K 11 pages Material contract
12/34/56
EX-10.1
from 8-K 32 pages Material contract
12/34/56
EX-10.1
from 8-K 40 pages Material contract
12/34/56
EX-10.3
from 10-Q 4 pages First Amendment to the License Agreement Uc Control No. 2020-04-0147
12/34/56
EX-10.2
from 10-Q 31 pages Exclusive License Between Yellowbrick Bio, LLC and Regents of the University of California for “Photochromic Ligands for Optical Control of Proetin and Cellular Function”
12/34/56
EX-10.2
from 8-K 18 pages Exclusive License Agreement
12/34/56
EX-10.1
from 8-K 5 pages First Amendment
12/34/56
EX-10.4
from 8-K 11 pages Registration Rights Agreement
12/34/56
EX-10.3
from 8-K 32 pages Purchase Agreement
12/34/56
EX-10.2
from 8-K 10 pages Registration Rights Agreement Registration Rights Agreement (This "Agreement"), Dated as of February 2, 2023, by and Between Kiora Pharmaceuticals, Inc., a Delaware Corporation (The "Company"), and Lincoln Park Capital Fund, LLC, an Illinois Limited Liability Company (The “Buyer”). Whereas
12/34/56
EX-10.1
from 8-K 40 pages Securities Purchase Agreement
12/34/56
EX-10.1
from 8-K 10 pages November 17, 2022 [Name and Address of Warrant Holder] Re: Reprice and Reload Offer of Class a Common Stock Purchase Warrants to Whom It May Concern
12/34/56
EX-10.1
from 8-K 2 pages Material contract
12/34/56
EX-10.1
from 8-K 8 pages Consulting Agreement
12/34/56
EX-10.1
from 8-K 7 pages January 31, 2022 by Email
12/34/56
EX-10.1
from 8-K 8 pages Eyegate Pharmaceuticals, Inc. Employment Agreement
12/34/56
EX-10.1
from 10-Q 14 pages ​ Eyegate Pharmaceuticals, Inc. 2014 Equity Incentive Plan
12/34/56
EX-10.2
from 8-K 10 pages Strictly Confidential
12/34/56
EX-10.1
from 8-K 39 pages Securities Purchase Agreement
12/34/56
EX-10.1
from 8-K 12 pages Eyegate Pharmaceuticals, Inc. Employment Agreement
12/34/56